Ryvu Therapeutics S.A. (FRA:9Y4)

Market Cap	133.23M -7.6%
Revenue (ttm)	20.79M -14.0%
Net Income	-23.99M
EPS	-1.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	11.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	5.40
Previous Close	5.64
Day's Range	5.40 - 5.40
52-Week Range	4.75 - 7.89
Beta	n/a
RSI	54.22
Earnings Date	May 21, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 228
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9Y4

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Financial numbers in PLN